Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Mixed MA signals — sideways/transition
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹3,220.1 Cr | ₹3,059.3 Cr | ₹6,003.8 Cr | ₹3,888 Cr |
| Net Profit | ₹4.7 Cr | ₹46.9 Cr | ₹610.4 Cr | ₹403.2 Cr |
| EPS | — | ₹1.66 | ₹21.63 | ₹14.29 |
| Operating Profit | ₹199.9 Cr | ₹283.7 Cr | ₹1,175.1 Cr | ₹729.9 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 03 Oct 2025 | Interim Dividend - Rs 2.50 Per Share | INTERIM_DIVIDEND |
| 15 Sept 2025 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 13 Sept 2024 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 18 Sept 2023 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 12 Sept 2022 | Annual General Meeting/Dividend - Rs 2.50 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for GLENMARK
View AllGlenmark Pharmaceuticals launches Winlevi across key European markets
Glenmark Pharmaceuticals announced that its wholly owned subsidiary Glenmark Specialty S.A (GSSA) has launched Winlevi (clascoterone 10 mg/g cream) across key markets in Europe for the treatment of acne vulgaris.
Glenmark launches Winlevi in key European markets
Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced the launch of Winlevi (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (SIX: COPN) (Cosmo) in October 2025.
Glenmark Pharma Profit Expected To Soar 5x in Two Years, Says Motilal Oswal — Check Target Price
Glenmark Pharma's shares are likely to remain in focus after Motilal Oswal has reiterated its positive stance on the stock.